Taiwan
With a strong growth market for drug development, dense population, and a universal healthcare system, Taiwan is an ideal location for clinical trials.
With a strong growth market for drug development, dense population, and a universal healthcare system, Taiwan is an ideal location for clinical trials.
Taiwan is one of George Clinical’s fastest-growing Asian hubs. With a strong growth market for drug development, a dense population, and a universal healthcare system, Taiwan is an ideal location for clinical trials. George Clinical’s on-the-ground clinical team leader oversees a number of our CRAs and CTAs in delivering customer projects across Taiwan. The Center for Drug Evaluation (CDE) was established by the Ministry of Health and Welfare (MOHW) to assist the Taiwan Food and Drug Administration (TFDA) in the technical review of new drugs, medical devices and clinical trials to fulfill regulatory requirements.
The MOHW regularly accredits sites for clinical trial conduct, where the certificate is valid for four years. There are 128 qualified sites for conducting clinical trials in Taiwan. Known centers for excellence include the National Taiwan University Hospital, which currently runs more than 600 clinical trials, including 43 Phase I clinical trials; and Chang Gung Memorial Hospital, which currently runs more than 500 clinical trials. There is strong government support for clinical trials.
| Population | 23.5 million |
|---|---|
| Official Language | Mandarin Chinese (official), Taiwanese (Min), Hakka, Aboriginal dialects |
| Hospital Records Language | English and Traditional Chinese |
| Electronic Hospital Records | All Taiwanese hospitals utilize a standard form of electronic medical records |
| Site Network | Only accredited teaching hospitals are able to carry out human clinical trials. There are approximately 128 qualified clinical trial sites in Taiwan |
| In-country services | Clinical Operations Regulatory Services |
| GDP – per capita (US $) | $24,318 |
